104 related articles for article (PubMed ID: 21839894)
1. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
März W; Genser B; Drechsler C; Krane V; Grammer TB; Ritz E; Stojakovic T; Scharnagl H; Winkler K; Holme I; Holdaas H; Wanner C;
Clin J Am Soc Nephrol; 2011 Jun; 6(6):1316-25. PubMed ID: 21493741
[TBL] [Abstract][Full Text] [Related]
3. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?
Grover S; Coupal L; Lowensteyn I
Can J Cardiol; 2008 Dec; 24(12):891-8. PubMed ID: 19052668
[TBL] [Abstract][Full Text] [Related]
4. [Cost-effectiveness of atorvastatin against simvastatin as hypolipemic treatment in hypercholesterolemic patients in primary care].
Tárraga López PJ; Celada Rodríguez A; Cerdán Oliver M; Solera Albero J; Ocaña López JM; de Miguel Clavé J
Aten Primaria; 2001 Jan; 27(1):18-24. PubMed ID: 11218969
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia.
Nherera L; Calvert NW; Demott K; Humphries SE; Neil HA; Minhas R; Thorogood M
Curr Med Res Opin; 2010 Mar; 26(3):529-36. PubMed ID: 20014994
[TBL] [Abstract][Full Text] [Related]
6. Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India: Cost-Effectiveness Analysis.
Basu S; Bendavid E; Sood N
Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):541-51. PubMed ID: 26555122
[TBL] [Abstract][Full Text] [Related]
7. Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry.
Schaefer JR; Gitt AK; Sonntag F; Weizel A; Jannowitz C; Karmann B; Pittrow D; Bestehorn K
Vasc Health Risk Manag; 2013; 9():71-80. PubMed ID: 23459022
[TBL] [Abstract][Full Text] [Related]
8. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients.
Stam-Slob MC; Visseren FL; Wouter Jukema J; van der Graaf Y; Poulter NR; Gupta A; Sattar N; Macfarlane PW; Kearney PM; de Craen AJ; Trompet S
Clin Res Cardiol; 2017 Jan; 106(1):58-68. PubMed ID: 27554244
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events.
Gandhi SK; Jensen MM; Fox KM; Smolen L; Olsson AG; Paulsson T
Clinicoecon Outcomes Res; 2012; 4():1-11. PubMed ID: 22347800
[TBL] [Abstract][Full Text] [Related]
10. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
; Mihaylova B; Briggs A; Armitage J; Parish S; Gray A; Collins R
BMJ; 2006 Dec; 333(7579):1145. PubMed ID: 17098764
[TBL] [Abstract][Full Text] [Related]
11. The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target.
Lum CJ; Nakagawa K; Shohet RV; Seto TB; Taira DA
Hawaii J Med Public Health; 2017 Apr; 76(4):99-102. PubMed ID: 28428922
[TBL] [Abstract][Full Text] [Related]
12. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.
Cobiac LJ; Magnus A; Barendregt JJ; Carter R; Vos T
BMC Public Health; 2012 Jun; 12():398. PubMed ID: 22657090
[TBL] [Abstract][Full Text] [Related]
13. Using the Payoff Time in Decision-Analytic Models: A Case Study for Using Statins in Primary Prevention.
Thompson A; Guthrie B; Payne K
Med Decis Making; 2017 Oct; 37(7):759-769. PubMed ID: 28441087
[TBL] [Abstract][Full Text] [Related]
14. Decision-making using absolute cardiovascular risk reduction and incremental cost-effectiveness ratios: a case study.
Ker JA; Oosthuizen H; Rheeder P
Cardiovasc J Afr; 2008; 19(2):97-101. PubMed ID: 18516355
[TBL] [Abstract][Full Text] [Related]
15. Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction (HARP-2) trial: study protocol for a randomized controlled trial.
McAuley DF; Laffey JG; O'Kane CM; Cross M; Perkins GD; Murphy L; McNally C; Crealey G; Stevenson M; ;
Trials; 2012 Sep; 13():170. PubMed ID: 22985805
[TBL] [Abstract][Full Text] [Related]
16. Comparing Strategies for Lipid Lowering in Argentina: An Analysis from the CVD Policy Model-Argentina.
Konfino J; Fernandez A; Penko J; Mason A; Martinez E; Coxson P; Heller D; Moran A; Bibbins-Domingo K; Pérez-Stable EJ; Mejía R
J Gen Intern Med; 2017 May; 32(5):524-533. PubMed ID: 27853916
[TBL] [Abstract][Full Text] [Related]
17. The pharmacodynamic and clinical trial evidence for statin dose.
Dimmitt SB; Stampfer HG; Warren JB
Br J Clin Pharmacol; 2018 Jun; 84(6):1128-1135. PubMed ID: 29393975
[TBL] [Abstract][Full Text] [Related]
18. [Effectiveness of statin treatment strategies for primary prevention of cardiovascular diseases in a community-based Chinese population: A decision-analytic Markov model].
Gong C; Liu QP; Wang JM; Liu XF; Zhang ML; Yang H; Shen P; Lin HB; Tang X; Gao P
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 54(3):443-449. PubMed ID: 35701120
[TBL] [Abstract][Full Text] [Related]
19. Exploring the Evolution of Statin Pricing in Australia: Observations of Price Disclosure Effects on Pharmaceutical Benefits Scheme Expenditure.
Lee L; Kim H
Value Health Reg Issues; 2024 Mar; 40():27-34. PubMed ID: 37972431
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study.
Barton P; Andronis L; Briggs A; McPherson K; Capewell S
BMJ; 2011 Jul; 343():d4044. PubMed ID: 21798967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
